 ROCKVILLE, Md. and BEIJING, March 24, 2021 PRNewswire -- CASI Pharmaceuticals, Inc. Nasdaq: CASI, a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of 2.05 per share. 